Analyst Research

Report Title Price
Provider: New Constructs, LLC
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

CombiMatrix Corp 's Pediatric development disorders analysis test granted conditional approval from New York State Department of Health


Tuesday, 15 Jul 2014 08:00am EDT 

CombiMatrix Corp:Says its chromosomal microarray analysis (CMA) test to identify development disorders in pediatric patients, the CombiSNP Array for Pediatric Analysis, has received conditional approval from the New York Department of Health for testing on patient samples.CMA testing for pediatric development disorders, such as its CombiSNP CMA test, is recommended by the American College of Medical Genetics for individuals with developmental delays, birth defects, physical deformities or autism or autism spectrum disorder.Under conditional approval, CombiMatrix will be able to market the test in New York while the test is under Clinical Laboratory Reference System review.Upon completion of the review, either the test will receive full marketing approval or additional information will be required in order to achieve final approval. 

Company Quote

1.77
 --
4 May 2015